You just read:

ContraVir Pharmaceuticals Expands Patient Enrollment Criteria for Ongoing Phase 3 Clinical Study of FV-100 for Treating Shingles

News provided by

ContraVir Pharmaceuticals, Inc.

Jun 16, 2016, 06:00 ET